Olivia Veit1,2,3,4, Cristina Domingo5, Matthias Niedrig5, Cornelia Staehelin1, Beat Sonderegger1, Delphine Héquet6, Marcel Stoeckle7, Alexandra Calmy8, Veronique Schiffer8, Enos Bernasconi9, Domenica Flury10, Christoph Hatz2,3,4, Marcel Zwahlen11, Hansjakob Furrer1. 1. Department of Infectious Diseases, Bern University Hospital, University of Bern. 2. Department of Medicine, Swiss Tropical and Public Health Institute. 3. University of Basel, Switzerland. 4. Institute of Epidemiology, Biostatistics and Prevention, University of Zürich, Switzerland. 5. Robert Koch Institute, Berlin, Germany. 6. Division of Infectious Diseases, University Hospital of Lausanne. 7. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University Basel. 8. Division of Infectious Diseases, University Hospital of Geneva. 9. Division of Infectious Diseases, Regional Hospital of Lugano. 10. Division of Infectious Diseases, Cantonal Hospital of St Gallen. 11. Institute of Social and Preventive Medicine, University of Bern, Switzerland.
Abstract
Background: In human immunodeficiency virus (HIV)-infected individuals, the immune response over time to yellow fever vaccination (YFV) and the necessity for booster vaccination are not well understood. Methods: We studied 247 participants of the Swiss HIV Cohort Study (SHCS) with a first YFV after HIV diagnosis and determined their immune responses at 1 year, 5 years, and 10 years postvaccination by yellow fever plaque reduction neutralization titers (PRNTs) in stored blood samples. A PRNT of 1:≥10 was regarded as reactive and protective. Predictors of vaccination response were analyzed with Poisson regression. Results: At vaccination, 82% of the vaccinees were taking combination antiretroviral therapy (cART), 83% had suppressed HIV RNA levels (<400 copies/mL), and their median CD4 T-cell count was 536 cells/μL. PRNT was reactive in 46% (95% confidence interval [CI], 38%-53%) before, 95% (95% CI, 91%-98%) within 1 year, 86% (95% CI, 79%-92%) at 5 years, and 75% (95% CI, 62%-85%) at 10 years postvaccination. In those with suppressed plasma HIV RNA at YFV, the proportion with reactive PRNTs remained high: 99% (95% CI, 95%-99.8%) within 1 year, 99% (95% CI, 92%-100%) at 5 years, and 100% (95% CI, 86%-100%) at 10 years. Conclusions: HIV-infected patients' long-term immune response up to 10 years to YFV is primarily dependent on the control of HIV replication at the time of vaccination. For those on successful cART, immune response up to 10 years is comparable to that of non-HIV-infected adults. We recommend a single YFV booster after 10 years for patients vaccinated on successful cART, whereas those vaccinated with uncontrolled HIV RNA may need an early booster.
Background: In human immunodeficiency virus (HIV)-infected individuals, the immune response over time to yellow fever vaccination (YFV) and the necessity for booster vaccination are not well understood. Methods: We studied 247 participants of the Swiss HIV Cohort Study (SHCS) with a first YFV after HIV diagnosis and determined their immune responses at 1 year, 5 years, and 10 years postvaccination by yellow fever plaque reduction neutralization titers (PRNTs) in stored blood samples. A PRNT of 1:≥10 was regarded as reactive and protective. Predictors of vaccination response were analyzed with Poisson regression. Results: At vaccination, 82% of the vaccinees were taking combination antiretroviral therapy (cART), 83% had suppressed HIV RNA levels (<400 copies/mL), and their median CD4 T-cell count was 536 cells/μL. PRNT was reactive in 46% (95% confidence interval [CI], 38%-53%) before, 95% (95% CI, 91%-98%) within 1 year, 86% (95% CI, 79%-92%) at 5 years, and 75% (95% CI, 62%-85%) at 10 years postvaccination. In those with suppressed plasma HIV RNA at YFV, the proportion with reactive PRNTs remained high: 99% (95% CI, 95%-99.8%) within 1 year, 99% (95% CI, 92%-100%) at 5 years, and 100% (95% CI, 86%-100%) at 10 years. Conclusions: HIV-infectedpatients' long-term immune response up to 10 years to YFV is primarily dependent on the control of HIV replication at the time of vaccination. For those on successful cART, immune response up to 10 years is comparable to that of non-HIV-infected adults. We recommend a single YFV booster after 10 years for patients vaccinated on successful cART, whereas those vaccinated with uncontrolled HIV RNA may need an early booster.
Authors: Elien Lecomte; Guy Laureys; Frederick Verbeke; Cristina Domingo Carrasco; Marjan Van Esbroeck; Ralph Huits Journal: J Travel Med Date: 2020-11-09 Impact factor: 8.490
Authors: Andrew Atkinson; Jose M Miro; Amanda Mocroft; Peter Reiss; Ole Kirk; Philippe Morlat; Jade Ghosn; Christoph Stephan; Cristina Mussini; Anastasia Antoniadou; Katja Doerholt; Enrico Girardi; Stéphane De Wit; David Kraus; Marcel Zwahlen; Hansjakob Furrer Journal: J Int AIDS Soc Date: 2021-06 Impact factor: 5.396
Authors: Kristen W Cohen; Susanne L Linderman; Zoe Moodie; Julie Czartoski; Lilin Lai; Grace Mantus; Carson Norwood; Lindsay E Nyhoff; Venkata Viswanadh Edara; Katharine Floyd; Stephen C De Rosa; Hasan Ahmed; Rachael Whaley; Shivan N Patel; Brittany Prigmore; Maria P Lemos; Carl W Davis; Sarah Furth; James B O'Keefe; Mohini P Gharpure; Sivaram Gunisetty; Kathy Stephens; Rustom Antia; Veronika I Zarnitsyna; David S Stephens; Srilatha Edupuganti; Nadine Rouphael; Evan J Anderson; Aneesh K Mehta; Jens Wrammert; Mehul S Suthar; Rafi Ahmed; M Juliana McElrath Journal: Cell Rep Med Date: 2021-07-03